Open company graph database — free web & API
Login

Sumitomo Dainippon Pharma Co., Ltd.

大日本住友製薬株式会社Sumitomo PharmaAlias住友ファーマ株式会社Alias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
4,042
Related companies
17
§01

Basic information

BASIC
Head office
Chief executive
Capital
Employees (non-consolidated)
4,042 people
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

60
Pharmaceuticals businessVeterinary pharmaceuticalsFood additivesManufacturing and sales of industrial chemicalsCardiovascular and diabetes fieldPsychoneurological fieldImmunity (inflammation and allergy) fieldCancer and infectious disease fieldRegenerative and cell medicine fieldCDMO businessRegenerative and cell medicine manufacturing plantCancer therapeuticsPsychoneurological disordersRegenerative and cell medicinesRegenerative and cell medicineCDMORegenerative and cell medicine manufacturingResearch and development in regenerative and cell medicine fieldAdvanced prostate cancer therapeuticsOveractive bladder therapeuticsUterine fibroid and endometriosis treatment drugCultured human thymus tissue for pediatric congenital athymiaPsychiatric and neurological disorder treatment drugiPSC-derived productGynecological disorder treatment drugUrological disorder treatment drugDiabetes treatment drugRare disease treatment drugInfectious disease treatment drugUniversal influenza vaccineMalaria vaccineProduct design and process development to make medicines easier to useApproval applications to regulatory authorities in each countryWe supply products consistently under rigorous quality management.Under stringent quality control, we consistently produce high-quality medicines within a global supply chain from raw material procurement to logistics.Providing medicines to medical institutions and pharmacies nationwide.Reliability assuranceStable supplyWe guarantee the reliability of products and information globally from development to post-marketing.Establishing a global quality assurance and audit system that delivers peace of mind.Manage safety information such as adverse reactions from the development (clinical trial) stage through post-manufacturing and sales, and implement proactive safety measures and information provision.EnvironmentSocial ContributionPharmaceutical BusinessInformation Provision ActivitiesKey Areas of Japanese BusinessProduct LineupResearch and DevelopmentPharmaceutical ProductionUnited StatesRuzudaZepirionZepirion TRIRonasentapeTuwimigOzenpick Subcutaneous InjectionMetglucoUgoobi Subcutaneous InjectionAgarsidase Beta BS Intravenous Injection "JCR"Izcargo
§04

Related companies

17 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
SMP Associates Co., Ltd.
Group
Sumitomo Pharma America, Inc.
Group
Sumitomo Pharma Pro-Mo Co., Ltd.
Group
RACTHERA Corporation
Group
CocoWork Inc.
Group
S-RACMO Corporation
Group
SMP Business Partners Co., Ltd.
Group
Marubeni Pharmaceuticals Inc.
Group
JCRファーマ株式会社
Alliance
Roivant Sciences Ltd.
Alliance
Carnava BioScience Inc.
Alliance
Novo Nordisk Pharma Co., Ltd.
Alliance
Nikka Kibaios Corporation
Alliance
ポクセル社
Alliance
Janssen Pharma Co., Ltd.
Alliance
株式会社ヘリオス
Alliance
Hitachi Ltd.
Alliance
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

45 EVENTS

(Meiji 30, May 14) Establishment: Osaka Seiyaku Co., Ltd. was founded in 1897 by 21 prominent pharmaceutical families in Osaka's Doushou Town.Sources

Established a pharmaceutical factory in Osaka's Ebira (formerly Osaka Factory, former Osaka General Center): Absorbed and merged with the semi-governmental and semi-private Dai Nippon Seiyaku Co., Ltd. in Tokyo, and renamed the company to Dai Nippon Seiyaku Co., Ltd.Sources

Absorbed and merged with Osaka Yakuhin Shiken Co., Ltd.Sources

Started chemical product business.Sources

New release of bronchodilator and antitussive 'Ephedrin Nagawari®'.Sources

1944: Sumitomo Chemical Industry Co., Ltd. (now Sumitomo Chemical Co., Ltd.) entered the pharmaceutical business.Sources

Started animal drug business.Sources

Started over-the-counter pharmaceutical business.Sources

Started food additive business.Sources

1961: Sumitomo Chemical Industry Co., Ltd. released chloroquine formulation (Kininon).Sources

Self-collection of thalidomide preparations (Isomin released in 1958, Provan M released in 1960): For information on the thalidomide drug disaster, see here (Sustainability 'Reliability Assurance').Sources

Established Dai Nippon Seiyaku Taiwan.Sources

Established Suzuka Factory (Suzuka City, Mie Prefecture).Sources

Completion of the Comprehensive Research Institute (Suita City, Osaka Prefecture).Sources

Started Laboratory Products business.Sources

New release of antibacterial chemotherapy agent 'Dulcol®'.Sources

1984: (Showa 59) Established on February 6: Sumitomo Chemical Industry Co., Ltd.'s pharmaceutical R&D and manufacturing division and the pharmaceutical sales division of Inabata Industry Co., Ltd., which was the sole distributor of Sumitomo Chemical's drugs, were inherited. Sumitomo Pharma Co., Ltd. was established in February 1984 and began operations on October 1 of the same year. New launch of transdermal analgesic anti-inflammatory cream 'Intaban® Cream' and new launch of cephalosporin antibiotic formulation 'Sepatren®'.Sources

1985: Completion of Ehime Bio Plant: New launch of hypertension, angina, arrhythmia treatment drug 'Armal® tablets'.Sources

Established Epilepsy Treatment Research Promotion Foundation.Sources

1987: New launch of natural interferon-α formulation 'Sumiferon®'.Sources

Established U.S. office: New release of peripheral circulation improvement agent 'Prolenar®'; new release of sustained ACE inhibitor antihypertensive 'Cetapril®'.Sources

New release of antiepileptic drug 'Exegran®'.Sources

1989: New launch of norepinephrine-acting neural function enhancer 'Dopus®'.Sources

1990: New launch of bone metabolism enhancer 'Daidroline®'.Sources

1991: Completion of Osaka Product Center.Sources

Completion of Central Logistics Center (now Kobe Logistics Center).Sources

1993: Transfer of feed additive business: New launch of hypertension, angina treatment drug 'Amrojin®'.Sources

1995: New launch of carbapenem antibiotic formulation 'Melopen®'.Sources

New release of sustained antihistamine 'Evaster®'.Sources

1996: New launch of serotonin-acting anxiolytic drug 'Sedil®'.Sources

100th anniversary of founding.Sources

1997: Completion of new Tokyo Product Center (now Tokyo Logistics Center): Establishment of Sumitomo Pharma UK Limited and opening of Beijing office.Sources

Opening of London and Beijing offices: New launch of gastrointestinal motility enhancer 'Gasmotin®'.Sources

New launch of sustained cancer pain treatment drug 'Cadien®'.Sources

1999: New launch of recombinant natural human growth hormone 'Growject®' and transfer of animal drug business: Establishment of Sumitomo Pharma America Limited.Sources

2000: Transfer of API business and commencement of sales of disinfectant 'Hibiten®'.Sources

2001: New launch of antipsychotic drug 'Ruran®' : Start of sales of H2 receptor antagonist 'Tagamet®' : Commencement of operations of Sumitomo Pharma Biomedicals Co., Ltd.Sources

New launch of inhaled steroid asthma treatment drug 'Cubal™'.Sources

Closure of Osaka plant (integrated into Suzuka plant): New launch of oral cancer pain treatment solution 'Opsu®'.Sources

2003: Took over active ingredient manufacturing from Sumitomo Chemical and established a new Oita plant.Sources

2004: 20th anniversary of commencement of operations.Sources

Transfer of general pharmaceutical business: New launch of sustained selective H1 receptor antagonist 'Evastel® OD tablets'.Sources

2005: Transferred sales of the over-the-counter pharmaceutical business.Sources

Sumitomo Pharma was born in October 2005 through the merger of Dai Nippon Pharmaceutical Co., Ltd. and Sumitomo Pharma Co., Ltd.Sources

Born in October 2005 through the merger of Dai Nippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd.Sources

§07

News

0 ARTICLES

There is no news.

§09

Sources & updates

SOURCES
↑